- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05106491
Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock (PulseSE)
Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock: A Randomized-Controlled Pilot Study
This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.
SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.
SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Fiona Bellando
- Numéro de téléphone: +49 6172 8868776
- E-mail: fiona.bellando@freseniusmedicalcare.com
Lieux d'étude
-
-
-
Essen, Allemagne, 45138
- Elisabeth-Krankenhaus Essen GmbH
-
Contact:
- Voigt Ingo, Dr med
- E-mail: I.Voigt@contilia.de
-
-
-
-
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Contact:
- Sandra Ofelia Rosillo Rodriguez, Dr. med.
- E-mail: sorrph17@gmail.com
-
-
-
-
-
Prague, Tchéquie, 150 06
- Motol University Hospital
-
Contact:
- Petr Ostadal, Prof. MD
- E-mail: petr.ostadal@lfmotol.cuni.cz
-
Prague, Tchéquie, 128 08
- General University Hospital Prague
-
Contact:
- Jan Bělohlávek, Prof. MD
- E-mail: jan.belohlavek@vfn.cz
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
The patients will be enrolled in 4 study centres across Europe.
Inclusion criteria:
-
Informed consent signed and dated by study patient/legal representative or investigator/authorized physician
-
Minimum age of 18 years
-
Patients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
-
Hemodynamic compromise (low cardiac output and elevated filling pressures):
- Cardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
- Central venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
-
Hypoperfusion:
- Lactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)
Exclusion criteria:
- In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
- Participation in an interventional clinical study during the preceding 30 days
- Previous participation in the same study
- Age > 75 years
- Out of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
- Non-cardiogenic causes of shock (sepsis, hypovolemia, etc.)
- Bradycardia or tachycardia as a cause of shock
- Fever (Body temperature > 38.0 °C) or other evidence of sepsis
- Onset of cardiogenic shock > 4 h before enrolment
- Lactate > 16 mmol/L
- Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
- Contraindications for anticoagulation
- Planned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
- Contraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SCS Group
Investigational group receiving Synchronized Cardiac Support treatment |
Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow |
|
Autre: Control Group VA-ECMO treatment
Control group receiving continous VA-ECMO treatment |
Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cardiocirculatory stabilization and end-organ perfusion
Délai: Baseline and during the ECMO treatment up to 7 days
|
Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA) |
Baseline and during the ECMO treatment up to 7 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Performance objective - Cardiocirculation
Délai: Baseline and during the ECMO treatment up to 7 days
|
Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization). |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - Cardiac Output
Délai: Baseline and during the ECMO treatment up to 7 days
|
Cardiac output measured using a pulmonary artery catheter (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - organ perfusion
Délai: Baseline and during the ECMO treatment up to 7 days
|
Improvement of end-organ perfusion |
Baseline and during the ECMO treatment up to 7 days
|
|
Blood gas analysis
Délai: Baseline and during the ECMO treatment up to 7 days
|
Assessment of blood gas parameters by arterial blood gas analysis |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - blood flow
Délai: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Pump speed
Délai: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Circuit pressures
Délai: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg) |
Baseline and during the ECMO treatment up to 7 days
|
|
Safety objectives
Délai: Baseline and during the ECMO treatment up to 7 days
|
Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO |
Baseline and during the ECMO treatment up to 7 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ingo Voigt, Dr. med., Elisabeth-Krankenhaus Essen
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CS-SCS-02-EU
- CIV-26-06-058894 (Autre identifiant: Eudamed-ID)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .